These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1972362)

  • 1. Leishmania major: nature of immunity induced by immunization with a mutagenized avirulent clone of the parasite in mice.
    McGurn M; Boon T; Louis JA; Titus RG
    Exp Parasitol; 1990 Jul; 71(1):81-9. PubMed ID: 1972362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major.
    Kimsey PB; Theodos CM; Mitchen TK; Turco SJ; Titus RG
    Infect Immun; 1993 Dec; 61(12):5205-13. PubMed ID: 7901166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity.
    Titus RG; Müller I; Kimsey P; Cerny A; Behin R; Zinkernagel RM; Louis JA
    Eur J Immunol; 1991 Mar; 21(3):559-67. PubMed ID: 1672641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
    Alexander J; Kaye PM
    Clin Exp Immunol; 1985 Sep; 61(3):674-82. PubMed ID: 3907906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis.
    Dhaliwal JS; Liew FY
    Infect Immun; 1987 Mar; 55(3):645-51. PubMed ID: 3818088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
    Liew FY; Dhaliwal JS
    J Immunol; 1987 Jun; 138(12):4450-6. PubMed ID: 3295049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
    J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.
    Rostamian M; Jafari D; Abolghazi M; Farahani H; Niknam HM
    Parasitol Res; 2018 Sep; 117(9):2949-2956. PubMed ID: 29978420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells.
    Bogdan C; Schröppel K; Lohoff M; Röllinghoff M; Solbach W
    Eur J Immunol; 1990 Dec; 20(12):2533-40. PubMed ID: 1980108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P; Pearce E; Natovitz P; Sher A
    J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells.
    Müller I; Pedrazzini T; Kropf P; Louis J; Milon G
    Int Immunol; 1991 Jun; 3(6):587-97. PubMed ID: 1909563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic immunization against experimental leishmaniasis. VI. Comparison of protective and disease-promoting T cells.
    Liew FY; Hodson K; Lelchuk R
    J Immunol; 1987 Nov; 139(9):3112-7. PubMed ID: 3312413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy between activated Leishmania major-specific CD4+ T lymphocytes and bone-marrow-derived cells in the exacerbation of murine cutaneous leishmaniasis.
    Mendonça SC; Titus RG; Louis JA
    Res Immunol; 1990; 141(9):865-78. PubMed ID: 1983098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity.
    Titus RG; Lima GC; Engers HD; Louis JA
    J Immunol; 1984 Sep; 133(3):1594-600. PubMed ID: 6205088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY; Howard JG; Hale C
    J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge.
    Rivier D; Shah R; Bovay P; Mauel J
    Parasite Immunol; 1993 Feb; 15(2):75-84. PubMed ID: 8446467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The route of Leishmania tropica infection determines disease outcome and protection against Leishmania major in BALB/c mice.
    Mahmoudzadeh-Niknam H; Khalili G; Abrishami F; Najafy A; Khaze V
    Korean J Parasitol; 2013 Feb; 51(1):69-74. PubMed ID: 23467583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
    Mahmoudzadeh-Niknam H; Kiaei SS; Iravani D
    Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.
    Scott P; Caspar P; Sher A
    J Immunol; 1990 Feb; 144(3):1075-9. PubMed ID: 2295814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific suppressor T cells for delayed-type hypersensitivity in susceptible mice immunized against cutaneous leishmaniasis.
    Dhaliwal JS; Liew FY; Cox FE
    Infect Immun; 1985 Aug; 49(2):417-23. PubMed ID: 3160663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.